Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC16A1 | P53985 | 4/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.43 |
| ▸ | SLC16A7 | O60669 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5405558 | 0.88 | SLC16A1 (0.47) | SLC16A1CYP3A4CYP2C9SLC16A7 | |
| SCHEMBL5407647 | 0.84 | PDE1A (0.39) | — | |
| SCHEMBL5395864 | 0.84 | SLC16A1 (0.47) | SLC16A1 | |
| SCHEMBL5418116 | 0.82 | SLC16A1 (0.46) | SLC16A1 | |
| SCHEMBL5400061 | 0.81 | SLC16A1 (0.43) | SLC16A1CYP3A4CYP2C9 | |
| SCHEMBL5407500 | 0.81 | SLC16A1 (0.45) | SLC16A1 | |
| SCHEMBL5407560 | 0.81 | SLC16A1 (0.45) | SLC16A1 | |
| SCHEMBL5415088 | 0.80 | SLC16A1 (0.46) | SLC16A1 | |
| SCHEMBL5398859 | 0.80 | SLC16A1 (0.45) | SLC16A1CYP3A4CYP2C9SLC16A7 | |
| SCHEMBL5403810 | 0.79 | SLC16A1 (0.45) | SLC16A1CYP3A4CYP2C9SLC16A7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7285558-B2 | Pyrazolo[3,4-d]pyrimidines inhibiting H. pylori infections | ASTRAZENECA AB (SE) | 2007-10-23 | — | — | US | disclosed |
| US-20040254183-A1 | Pyrazolo[3,4-d]pyrimidines inhibiting h. pylori infections | ASTRAZENECA AB (SE) | 2004-12-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040254183-A1 | Pyrazolo[3,4-d]pyrimidines inhibiting h. pylori infections | DPYD, HPGDS, PGC | SLC16A1 4140/4885CYP3A4 129/4885CYP2C9 82/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.